Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 25.81M | Sales 2025 * | 77.52M | Capitalization | 394M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -193M | EV / Sales 2024 * | 15.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.08 x |
P/E ratio 2024 * |
-2.25
x | P/E ratio 2025 * |
-2.52
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |